Drugs / Mifepristone
Mifepristone
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | MIFEPREX | — | 2016-03-29 | fda.gov ↗ |
| Approved | US (FDA) | MIFEPREX | — | 2000-09-28 | fda.gov ↗ |
Trials 141 · started per year
today
US approved 2000
1
1
1
1
4
8
8
2
8
9
11
7
6
5
12
5
3
6
10
5
2
5
8
3
4
3
1
1
1
19921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06616077 | Jun 2022 → Apr 2023 | endometrial disorder, progesterone resistance | Reproductive Health Research Insritute, Chile | Completed | No outcome recorded |
| Phase 0 | NCT05151016 | Dec 2021 → Dec 2023 | adenomyosis | Women's Hospital School Of Medicine Zhejiang University | Unknown | No outcome recorded |
| Phase 0 | NCT01138553 | Jun 2010 → Jun 2014 | ductal breast carcinoma in situ, invasive breast carcinoma | University of California, San Diego | Terminated | No outcome recorded Stop: Enrollment |
| Phase 115 trials | ||||||
| Phase 1 | NCT06502158 | Oct 2024 → Oct 2026 expected | — | Montefiore Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04254627 | Sep 2021 → Sep 2025 | persian gulf syndrome | Nova Southeastern University | Completed | No outcome recorded |
| Phase 1 | NCT04255498 | Oct 2017 → Aug 2019 | occupational disorder, persian gulf syndrome | South Florida Veterans Affairs Foundation for Research and Education | Unknown | No outcome recorded |
| Phase 1 | NCT03258372 | Aug → Nov 2017 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03259542 | Aug → Dec 2017 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03508635 | Sep 2014 → Dec 2015 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02099825 | Jan 2014 → Oct 2022 | anxiety disorder | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT02014337 | Jan 2014 → Dec 2017 | breast cancer, malignant epithelial tumor of ovary, non-small cell lung carcinoma, prostate cancer +2 | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02046421 | Nov 2013 → May 2018 | fallopian tube carcinoma, male breast carcinoma, malignant epithelial tumor of ovary, primary peritoneal carcinoma | University of Chicago | Completed | No outcome recorded |
| Phase 1 | NCT01988610 | Oct 2013 → Feb 2017 | depressive disorder | Stanford University | Completed | No outcome recorded |
| Phase 1 | NCT01493310 | Nov 2011 → May 2018 | female breast carcinoma, male breast carcinoma | University of Chicago | Completed | No outcome recorded |
| Phase 1 | NCT00698022 | Nov 2008 → Feb 2009 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00752843 | Sep → Nov 2008 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00592215 | Mar 2008 → Apr 2010 | — | Johns Hopkins University | Withdrawn | No outcome recorded |
| Phase 1 | NCT00554177 | Sep 2007 → Sep 2008 | post-traumatic stress disorder | Antonia New | Completed | No outcome recorded |
| Phase 1/25 trials · 3 missed | ||||||
| Phase 1/2 | NCT02012296 | Dec 2013 → Jun 2019 | hormone-resistant prostate carcinoma | University of Chicago | Completed | Missed primary |
| Phase 1/2 | NCT01333098 | Sep 2012 → Apr 2013 | anxiety disorder | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT01419535 | Nov 2011 → Nov 2015 | diabetes mellitus | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | Missed primary |
| Phase 1/2 | NCT00721201 | Nov 2008 → Mar 2010 | Cushing syndrome | Sheffield Teaching Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 1/2 | NCT00099645 | ? → Aug 2005 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 229 trials · 2 missed | ||||||
| Phase 2 | NCT06689254 | Nov 2024 → Sep 2026 overdue | post-traumatic stress disorder | Christiaan Vinkers | Recruiting | No outcome recorded |
| Phase 2 | NCT06099769 | Oct 2023 → Oct 2027 expected | breast cancer | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05177510 | Aug 2023 → Dec 2026 expected | — | Chelsea and Westminster NHS Foundation Trust | Recruiting | No outcome recorded |
| Phase 2 | NCT05217758 | Dec 2021 → Aug 2024 | major depressive disorder | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Phase 2 | NCT04588688 | May → Aug 2021 | secondary adrenal insufficiency | Tobias Else | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04676776 | Jan → Dec 2021 | — | Gynuity Health Projects | Unknown | No outcome recorded |
| Phase 2 | NCT03972358 | Feb 2020 → Dec 2021 | menstrual disorder | Gynuity Health Projects | Unknown | No outcome recorded |
| Phase 2 | NCT03714880 | Apr 2019 → Feb 2021 | — | University of California, Davis | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03225547 | Feb 2018 → Sep 2025 | triple-negative breast carcinoma | University of Chicago | Terminated | No outcome recorded |
| Phase 2 | NCT02788981 | Mar 2017 → Dec 2022 overdue | breast cancer | University of Chicago | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03052400 | Feb 2017 → Mar 2021 | type 2 diabetes mellitus | Charles Drew University of Medicine and Science | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02642939 | Dec 2015 → Oct 2020 | non-small cell lung carcinoma | Check, Jerome H., M.D., Ph.D. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02354170 | Jan 2015 → Apr 2017 | central serous chorioretinopathy | Roger Goldberg, M.D., MBA | Completed | No outcome recorded |
| Phase 2 | NCT01898312 | Sep 2013 → Dec 2021 | hereditary breast ovarian cancer syndrome | Karolinska Institutet | Completed | No outcome recorded |
| Phase 2 | NCT01931657 | Aug 2013 → Dec 2015 | — | Karolinska Institutet | Completed | No outcome recorded |
| Phase 2 | NCT01739335 | Nov 2012 → Sep 2016 | post-traumatic stress disorder | VA Office of Research and Development | Completed | Missed primary |
| Phase 2 | NCT01294319 | Jan 2011 → Aug 2016 | glucocorticoid resistance | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | Missed primary |
| Phase 2 | NCT01212588 | Sep 2010 → Sep 2016 | borderline personality disorder | Indiana University | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00881140 | Apr 2009 → May 2012 | uterine benign neoplasm, vaginal disorder | BioPro Medical Ltd | Completed | No outcome recorded |
| Phase 2 | NCT00833339 | May 2008 → Oct 2015 | post-traumatic stress disorder | James J. Peters Veterans Affairs Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00422201 | May 2007 → Apr 2012 | ectopic Cushing syndrome | HRA Pharma | Terminated | No outcome recorded |
| Phase 2 | NCT00459290 | May 2007 → Jul 2010 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00455442 | Mar → Jul 2007 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00330993 | Mar → Aug 2006 | — | University of Pittsburgh | Completed | No outcome recorded |
| Phase 2 | NCT00140478 | Feb 2005 → Jun 2006 | prostate adenocarcinoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00219778 | Dec 2004 → Feb 2010 | leiomyoma | Poitiers University Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT00105105 | Apr 2003 → Nov 2005 | Alzheimer disease | Corcept Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT00043654 | Aug 2002 → Jun 2007 | bipolar disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 2 | NCT00505739 | Sep 2001 → Oct 2007 | endometrial cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2/37 trials · 1 met primary · 1 missed | ||||||
| Phase 2/3 | NCT06492889 | Jul 2024 → Jun 2025 overdue | pregnancy disorder | Gynuity Health Projects | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT03520439 | May 2018 → Jul 2019 | adenomyosis | xinmei zhang | Completed | Met primary |
| Phase 2/3 | NCT02271958 | Nov 2010 → Oct 2013 | endometriosis | Mediterranea Medica S. L. | Completed | No outcome recorded |
| Phase 2/3 | NCT01786226 | Mar 2010 → Mar 2012 | uterine benign neoplasm | Mediterranea Medica S. L. | Terminated | No outcome recorded |
| Phase 2/3 | NCT00886873 | May 2008 → Apr 2009 | uterine benign neoplasm | Mediterranea Medica S. L. | Completed | No outcome recorded |
| Phase 2/3 | NCT00712595 | Jan 2007 | leiomyoma | Mediterranea Medica S. L. | Completed | No outcome recorded |
| Phase 2/3 | NCT00725270 | Apr 1998 → May 2009 | major depressive disorder, psychotic disorder | Stanford University | Terminated | Missed primary Stop: Business |
| Phase 321 trials | ||||||
| Phase 3 | NCT07506512 | Jul 2027 → Jul 2031 expected | pregnancy loss, recurrent, 4 | University of Pennsylvania | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06394999 | May 2025 → Jun 2027 expected | — | Leiden University Medical Center | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05016349 | Aug → Oct 2021 | female breast carcinoma | Mahmoud Ramadan mohamed Elkazzaz | Unknown | No outcome recorded |
| Phase 3 | NCT03269279 | May 2017 → Dec 2019 | — | Gynuity Health Projects | Unknown | No outcome recorded |
| Phase 3 | NCT02985229 | Oct 2016 → Jul 2017 | — | Gynuity Health Projects | Completed | No outcome recorded |
| Phase 3 | NCT01925092 | Aug 2013 → Dec 2016 | Cushing disease due to pituitary adenoma | Corcept Therapeutics | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01795599 | May 2013 → Feb 2015 | — | Assistance Publique Hopitaux De Marseille | Unknown | No outcome recorded |
| Phase 3 | NCT01436279 | Jul 2011 → Aug 2013 | — | Boston University | Completed | No outcome recorded |
| Phase 3 | NCT00957346 | Feb 2011 → Jan 2012 | — | Gynuity Health Projects | Terminated | No outcome recorded |
| Phase 3 | NCT01371565 | Nov 2010 → Jun 2012 | Cushing disease due to pituitary adenoma | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT00936741 | Jul 2009 → Sep 2012 | Cushing syndrome | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT00920465 | Jun 2009 → Dec 2011 | — | Western Galilee Hospital-Nahariya | Unknown | No outcome recorded |
| Phase 3 | NCT00569582 | Dec 2007 → Jan 2011 | Cushing syndrome | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT00128505 | Aug 2005 → Nov 2006 | major depressive disorder, psychotic disorder | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT00867360 | Aug 2005 → May 2009 | depressive disorder, psychotic disorder | Stanford University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00208156 | May 2005 → Nov 2006 | major depressive disorder | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT00146523 | May 2005 → Jul 2006 | major depressive disorder | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT00130676 | Sep 2004 → Jun 2006 | major depressive disorder, psychotic disorder | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT00128479 | Sep 2004 → Jan 2007 | major depressive disorder, psychotic disorder | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT00133705 | Jul 2003 → Jun 2010 | leiomyoma | University of Rochester | Completed | No outcome recorded |
| Phase 3 | NCT03015701 | Aug 1992 → Oct 2001 | meningioma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 434 trials · 3 met primary · 2 missed | ||||||
| Phase 4 | NCT07671989 | Jun → Dec 2026 expected | menstrual disorder | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 4 | NCT05772169 | Mar 2023 → Nov 2024 | Cushing syndrome, type 2 diabetes mellitus | Corcept Therapeutics | Completed | Met primary |
| Phase 4 | NCT05119439 | Oct 2022 → Jun 2023 | — | Gynuity Health Projects | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT05322252 | Jul 2022 → Jun 2025 | pregnancy disorder with abortive outcome, preterm premature rupture of the membranes | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT05124314 | Oct 2021 → Oct 2023 | — | Clinical Hospital Merkur | Unknown | No outcome recorded |
| Phase 4 | NCT05046041 | Nov 2020 → Aug 2021 | — | Gynuity Health Projects | Completed | No outcome recorded |
| Phase 4 | NCT04458558 | Jun 2020 → Apr 2021 | pregnancy disorder | Center for Information and Counseling on Reproductive Health - Tanadgoma | Unknown | No outcome recorded |
| Phase 4 | NCT03913104 | Jan 2020 → Jul 2023 | pregnancy disorder | Daniel Grossman, MD | Completed | No outcome recorded |
| Phase 4 | NCT03829696 | Jan 2020 → Jan 2021 | — | University of California, San Francisco | Withdrawn | No outcome recorded |
| Phase 4 | NCT04063904 | Oct 2019 → Apr 2020 | — | Gynuity Health Projects | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03212352 | Jun 2018 → Jan 2020 | pregnancy disorder with abortive outcome | Radboud University Medical Center | Terminated | Met primary |
| Phase 4 | NCT03320057 | Jun 2018 → Jul 2020 | pregnancy disorder | Daniel Grossman | Completed | No outcome recorded |
| Phase 4 | NCT03346629 | Dec 2017 → Dec 2018 | — | Gynuity Health Projects | Completed | No outcome recorded |
| Phase 4 | NCT03210324 | Jun 2017 → Jan 2019 | leiomyoma | China Resources Zizhu Pharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03044093 | Jan 2017 → Jan 2019 | — | Rambam Health Care Campus | Unknown | No outcome recorded |
| Phase 4 | NCT02981030 | Nov 2016 → Jun 2017 | — | Gynuity Health Projects | Completed | No outcome recorded |
| Phase 4 | NCT02745093 | Sep → Dec 2016 | — | Ibis Reproductive Health | Unknown | No outcome recorded |
| Phase 4 | NCT02704481 | Jun 2016 → Jan 2019 | — | Gynuity Health Projects | Terminated | No outcome recorded Stop: Business |
| Phase 4 | NCT02342002 | Jan 2015 → Dec 2018 | pregnancy disorder with abortive outcome | Gynuity Health Projects | Terminated | No outcome recorded Stop: Business |
| Phase 4 | NCT02314754 | Dec 2014 → Apr 2016 | — | Gynuity Health Projects | Completed | No outcome recorded |
| Phase 4 | NCT02720991 | Jul 2014 → Apr 2015 | — | Gynuity Health Projects | Completed | No outcome recorded |
| Phase 4 | NCT01990560 | Nov 2013 → Sep 2016 | adrenal gland hyperfunction | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 4 | NCT01856985 | Apr → Sep 2013 | — | Gynuity Health Projects | Completed | No outcome recorded |
| Phase 4 | NCT01768299 | Feb 2013 → May 2014 | — | Gynuity Health Projects | Completed | No outcome recorded |
| Phase 4 | NCT01798017 | Nov 2012 → Jun 2015 | menstrual disorder | Gynuity Health Projects | Completed | No outcome recorded |
| Phase 4 | NCT01631682 | Nov 2010 → Jan 2015 | post-traumatic stress disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00997347 | Jul 2009 → Feb 2012 | — | Gynuity Health Projects | Completed | No outcome recorded |
| Phase 4 | NCT01387256 | May 2009 → Jul 2010 | — | Gynuity Health Projects | Completed | No outcome recorded |
| Phase 4 | NCT01490697 | Mar 2009 → Sep 2015 | post-traumatic stress disorder | Roger K. Pitman, MD | Completed | Missed primary |
| Phase 4 | NCT00691067 | May 2008 → Aug 2012 | persian gulf syndrome | Bronx Veterans Medical Research Foundation, Inc | Completed | Missed primary |
| Phase 4 | NCT00177372 | Jan → Sep 2005 | pregnancy disorder with abortive outcome | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00410345 | Aug 2004 → May 2008 | — | Hadassah Medical Organization | Completed | No outcome recorded |
| Phase 4 | NCT00269568 | Jun 2004 → Apr 2006 | — | University of Pittsburgh | Completed | Met primary |
| Phase 4 | NCT00190294 | Apr 2003 → Sep 2006 | pregnancy disorder | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase not applicable27 trials · 8 met primary · 1 missed | ||||||
| — | NCT05898321 | Jun 2023 → Dec 2024 | submucous uterine fibroid | Women's Hospital School Of Medicine Zhejiang University | Unknown | No outcome recorded |
| — | NCT05049980 | Nov 2021 → Feb 2022 | — | University Hospital, Toulouse | Completed | No outcome recorded |
| — | NCT03440866 | Mar 2018 → Dec 2021 | — | HaEmek Medical Center, Israel | Unknown | Missed primary |
| — | NCT03043014 | Jun 2017 → Mar 2019 | — | Assistance Publique Hopitaux De Marseille | Completed | Met primary |
| — | NCT02679092 | Apr 2016 → Feb 2020 | — | Stanford University | Withdrawn | No outcome recorded Stop: Business |
| — | NCT02651844 | Apr 2016 → Oct 2019 | breast cancer | Hospital Provincial Magdalena V. de Martínez | Completed | Met primary |
| — | NCT01862991 | Jul 2013 → Jun 2016 | — | Stanford University | Completed | No outcome recorded |
| — | NCT01811056 | Apr 2013 → Jul 2014 | — | Gynuity Health Projects | Completed | No outcome recorded |
| — | NCT01636063 | Jun 2012 → May 2014 | — | Boston University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01615731 | May 2012 → Jun 2013 | — | Stanford University | Completed | No outcome recorded |
| — | NCT01475318 | Oct 2011 → Jun 2012 | — | The University of Hong Kong | Unknown | No outcome recorded |
| — | NCT02219100 | Nov 2010 → Nov 2011 | — | Gynuity Health Projects | Completed | No outcome recorded |
| — | NCT02398838 | Dec 2009 → Apr 2012 | — | Gynuity Health Projects | Completed | No outcome recorded |
| — | NCT00986921 | Oct 2009 → Mar 2011 | — | Boston University | Completed | Met primary |
| — | NCT01173003 | Jun 2009 → Dec 2011 | — | Gynuity Health Projects | Completed | No outcome recorded |
| — | NCT00969982 | Jun 2009 → Jun 2013 | — | Gynuity Health Projects | Completed | Met primary |
| — | NCT00994734 | May 2009 → Feb 2011 | — | Gynuity Health Projects | Completed | No outcome recorded |
| — | NCT00832871 | Nov 2008 → Dec 2015 | cancer | New Mexico Cancer Research Alliance | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00784186 | Aug 2008 → Aug 2009 | — | Gynuity Health Projects | Completed | Met primary |
| — | NCT00680394 | Jul 2007 → May 2008 | — | Gynuity Health Projects | Completed | Met primary |
| — | NCT00468299 | Apr 2007 → Dec 2008 | pregnancy disorder with abortive outcome | Boston University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00386282 | Sep 2006 → Mar 2011 | — | Gynuity Health Projects | Completed | No outcome recorded |
| — | NCT00382538 | Mar 2005 → Nov 2006 | — | Boston University | Completed | Met primary |
| — | NCT00677755 | Oct 2004 → Sep 2007 | — | Taizhou Hospital | Completed | No outcome recorded |
| — | NCT01224509 | Sep 2004 → Mar 2005 | — | University of Southern California | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00383032 | Jan 2004 → Jun 2006 | — | Dartmouth-Hitchcock Medical Center | Completed | Met primary |
| — | NCT00186056 | Jan 2003 → May 2007 | major depressive disorder | Stanford University | Completed | No outcome recorded |
| Comparator or background therapy32 trials | ||||||
| Phase 0 | NCT03248713 Comparator | Nov 2017 → May 2019 | nicotine dependence | Yale University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00579475 Comparator | Nov 2004 → Jun 2007 | benign neoplasm of corpus uteri | Karolinska Institutet | Completed | No outcome recorded |
| Phase 1/2 | NCT03774745 Background | Feb → Jul 2019 | — | University of California, Davis | Terminated | No outcome recorded |
| Phase 1/2 | NCT02989662 Comparator | Sep 2017 → Jan 2024 | alcohol-related disorders | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1/2 | NCT02243709 Comparator | Sep 2014 → Dec 2021 | alcohol-related disorders | Brown University | Completed | No outcome recorded |
| Phase 2 | NCT02179749 Comparator | Sep 2014 → Nov 2019 | alcohol abuse, alcohol dependence | The Scripps Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT01548417 Comparator | Mar 2012 → Jul 2015 | alcohol dependence | The Scripps Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00352911 Comparator | Jul 2006 → Jun 2007 | HIV infectious disease | VGX Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00359125 Comparator | Jul 2006 → Dec 2010 | bipolar depression | University of British Columbia | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT01134198 Comparator | May 2010 → Sep 2016 | cocaine dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 3 | NCT05839899 Background | Aug 2023 → Jul 2024 | — | Planned Parenthood League of Massachusetts | Unknown | No outcome recorded |
| Phase 3 | NCT05097326 Comparator | Jun 2022 → Apr 2023 | — | Stanford University | Completed | No outcome recorded |
| Phase 3 | NCT05304273 Comparator | May 2022 → Jul 2024 | pregnancy disorder with abortive outcome | Calcutta National Medical College and Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03065660 Comparator | Sep 2017 → Jan 2020 | — | University of Birmingham | Completed | No outcome recorded |
| Phase 3 | NCT02633761 Comparator | Apr 2015 → Dec 2018 | pregnancy disorder with abortive outcome | Gynuity Health Projects | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT02012491 Comparator | Jan 2014 → May 2017 | pregnancy disorder with abortive outcome | University of Pennsylvania | Completed | No outcome recorded |
| Phase 3 | NCT00637494 Comparator | Mar 2008 → Jun 2014 | major depressive disorder, psychotic disorder | Corcept Therapeutics | Terminated | No outcome recorded |
| Phase 4 | NCT07174856 Comparator | Oct 2025 → Jan 2027 expected | — | Ibis Reproductive Health | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05341817 Comparator | Nov 2022 → Aug 2025 overdue | — | KK Women's and Children's Hospital | Recruiting | Missed primary |
| Phase 4 | NCT03134183 Background | Nov 2016 → Aug 2017 | — | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 4 | NCT02620904 Comparator | Jul 2016 → Oct 2019 | pregnancy disorder with abortive outcome | Montefiore Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02708446 Comparator | May 2014 → Dec 2016 | — | Gynuity Health Projects | Unknown | No outcome recorded |
| Phase 4 | NCT01920022 Background | Oct 2013 → Oct 2015 | — | Karolinska Institutet | Completed | Met primary |
| Phase 4 | NCT02412618 Comparator | Sep 2012 → Jan 2014 | — | Medstar Health Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT00784797 Comparator | Jan 2009 → Jun 2012 | — | Hadassah Medical Organization | Completed | No outcome recorded |
| — | NCT07646275 Comparator | Apr 2025 → Jan 2026 | habitual spontaneous abortion, pregnancy disorder with abortive outcome, pregnancy loss, recurrent, 4 | Harran University | Completed | No outcome recorded |
| — | NCT06733727 Comparator | Dec 2024 → Dec 2027 expected | — | The University of Hong Kong | Not yet recruiting | No outcome recorded |
| — | NCT04751500 Comparator | Jan 2021 → Nov 2022 | — | Birmingham Women's and Children's NHS Foundation Trust | Completed | No outcome recorded |
| — | NCT00482209 Comparator | May 2007 → Oct 2009 | — | Gynuity Health Projects | Completed | No outcome recorded |
| — | NCT00286208 Comparator | Aug 2005 → Jan 2008 | — | Gynuity Health Projects | Completed | No outcome recorded |
| — | NCT00285818 Comparator | Jan 2003 → Jan 2009 | major depressive disorder | Stanford University | Completed | No outcome recorded |
| — | NCT00945997 Comparator | Oct 2000 → Sep 2004 | — | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 11
| Date | Issuer | Release |
|---|---|---|
| 2026-06-06 | Corcept Therapeutics | Results Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym® corcept.com ↗ |
| 2025-06-23 | Corcept Therapeutics | Results Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85th Scientific Sessions with Simultaneous Publication in Diabetes Care corcept.com ↗
Patients who received Korlym exhibited a clinically meaningful and statistically significant improvement in hemoglobin A1c (HbA1c), which decreased 1.47 percent from baseline, compared to a 0.15 percent decrease in patients who received placebo (p-value: < 0.001). |
| 2024-12-12 | Corcept Therapeutics | Results Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes corcept.com ↗
CATALYST met its primary endpoint. |
| 2019-04-18 | Corcept Therapeutics | Results Corcept Therapeutics to Present Data at the 2019 American Association of Clinical Endocrinologists’ 28th Annual Congress corcept.com ↗
Mifepristone Provides Beneficial Clinical Improvement in Two Cushing Disease Cases in a Community Endocrinology Practice |
| 2019-03-20 | Corcept Therapeutics | Results Corcept Therapeutics Announces Poster Presentations at the 2019 Annual Meeting of the Endocrine Society Meeting corcept.com ↗
Sustained Clinical Improvement after Discontinuation of Mifepristone: Unexpected Remission of Hypercortisolism |
| 2016-12-10 | Corcept Therapeutics | Results Corcept Therapeutics Announces Encouraging Results of Phase 1/2 Trial of Mifepristone Plus Eribulin in Triple-Negative Breast Cancer corcept.com ↗
Four patients exhibited a partial response, defined as a 30 percent or greater reduction in tumor size, eight had stable disease and 11 had progressive disease. |
| 2016-06-02 | Corcept Therapeutics | Results Corcept Therapeutics Provides Update of Progress in Cortisol Modulation Oncology Program corcept.com ↗
Preliminary efficacy results in Phase 1/2 trial of mifepristone plus eribulin (Eisai’s Halaven®) to treat triple-negative breast cancer (TNBC) indicate combination is active; final results expected in mid-2016 |
| 2015-12-14 | Corcept Therapeutics | Results Corcept Therapeutics Announces Initial Efficacy Results in Phase 1/2 Trial of Mifepristone in Combination With Eribulin for the Treatment of Patients With Metastatic Triple-Negative Breast Cancer corcept.com ↗
At SABCS, the trial's investigators presented efficacy data from the 15 patients enrolled to-date with GR-positive TNBC who have been treated with the recommended dose (two patients from the trial's first phase and 13 from its second). |
| 2015-05-14 | Corcept Therapeutics | Results Corcept Therapeutics Announces Poster Presentations on Mifepristone for the Treatment of Patients with Cushing’s Syndrome at the 27th Annual American Association of Clinical Endocrinologists corcept.com ↗
Mifepristone re-established glycemic control in a Cushing’s syndrome patient that relapsed after a 21 month interruption |
| 2015-05-13 | Corcept Therapeutics | Results Corcept Therapeutics' Mifepristone Combined with Eribulin to Improve Antitumor Activity in Patients with Triple-Negative Breast Cancer corcept.com ↗
today announced results of a multi-center Phase 1/2 dose-escalation study of mifepristone and chemotherapy drug eribulin (Halaven®) that show it is well tolerated and clinically active in patients with triple-negative breast cancer. |
| 2014-05-07 | Corcept Therapeutics | Results Corcept Therapeutics Announces First Quarter 2014 Financial Results corcept.com ↗
The company also reported that it is discontinuing its Phase 3 psychotic depression study (Study 14) based on the recommendation of the study's data monitoring committee that the study was unlikely to meet its primary endpoint with statistical significance. |
All press releases naming this drug 16 releases
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 174 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mifépristone | “Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) vaginally 1-2 hours prior and placebo (buccal mint powder) buccally 1-2 hours prior to D&E” NCT03134183 ↗172“This mixed-methods study follows a prospective cohort of participants receiving Mifeprex® (mifepristone) by a clinician in advance of a potential unintended pregnancy.” NCT03829696 ↗ “Participants were randomized to receive cervical priming with 200 mg of oral mifepristone 36 hours or 400 micrograms buccal misoprostol 3 hours before surgery.” PMID 33957651 ↗ Jun 2021 “the recommended use of mifepristone or misoprostol as cervical preparation for the abortions after 12 weeks” NCT01795599 ↗ “The first regimen will include a 200 mg oral dose of mifepristone followed by 800 mcg buccal misoprostol.” NCT01387256 ↗ “The antiprogesterone, mifepristone, is one of the most promising drugs that have been tested.” NCT00579475 ↗ “Administration of oral Mifepristone 600 mg and oral Misoprostol 400 mcg concomitantly.” NCT03440866 ↗ “mifepristone (200mg orally) followed 24-48 hours later by misoprostol” NCT07174856 ↗ “oral administration of mifepristone 200 mg” NCT00945997 ↗ “Mifépristone versus Misoprostol” NCT03043014 ↗ “Mifepristone” NCT00359125 ↗ |
| Known as | C-1073 | “The purpose of this study is to evaluate the effects of C-1073 (Mifepristone) on cognition in patients with Alzheimer's disease (AD) who are also taking an acetylcholinesterase...” NCT00105105 ↗ |
| Known as | Corlux | “Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol.” NCT00146523 ↗4“Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol.” NCT00208156 ↗ “Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol.” NCT00128479 ↗ “Corlux (mifepristone) is a new medication” NCT00128505 ↗ “CORLUX (TM) (Mifepristone)” NCT00752843 ↗ |
| Known as | Korlym | “Mifepristone 300 MG [Korlym]” NCT05772169 ↗1“Korlym (mifepristone)” NCT01548417 ↗ |
| Known as | Medicane | “Medicane (mifepristone)” NCT00554177 ↗ |
| Known as | MFP | “Mifepristone (MFP) is currently used for medical abortion and for the treatment of Cushing disease.” NCT02651844 ↗ |
| Known as | Mifegyne | “Mifepristone (Mifegyne) 50 mg every other day for 3 months” NCT00579475 ↗ |
| Known as | Mifeprex | “Patients will receive Mifeprex® (mifepristone) by pharmacy rather than standard care at clinic visit” NCT03320057 ↗ |
| Known as | MifeprexⓇ | “Patients will have MifeprexⓇ (mifepristone) shipped to a preferred address via an online mail order pharmacy rather than standard care at clinic visit.” NCT03913104 ↗ |
| Known as | Mifepristone tablets | “Mifepristone tablets is developed by the China Resources Zizhu Pharmaceutical Co., Ltd.” NCT03210324 ↗ |
| Known as | Mifepristone, RU486 | “Mifepristone, RU486” NCT06733727 ↗ |
| Known as | RU-486 | “the purpose of this study is to determine the anti-HIV activity and safety of 3 different doses of mifepristone (also known as VGX-410 and RU486) in HIV infected people.” NCT00099645 ↗6“evaluates the effectiveness of mifepristone (RU 486) in rapidly reducing the symptoms associated with schizoaffective disorder.” NCT00725270 ↗ “Mifepristone, also known as RU-486, is a well-tolerated competitive progesterone receptor antagonist.” NCT05322252 ↗ “Mifepristone (RU-486) in Androgen Independent Prostate Cancer” NCT00140478 ↗ “mifepristone (RU-486), a glucocorticoid receptor antagonist” NCT00043654 ↗ “mifepristone (RU-486)” NCT00359125 ↗ “Mifepristone (RU-486)” NCT00867360 ↗ |
| Known as | VGX-410 | “the purpose of this study is to determine the anti-HIV activity and safety of 3 different doses of mifepristone (also known as VGX-410 and RU486) in HIV infected people.” NCT00099645 ↗1“two doses of orally administered mifepristone (VGX-410) (300 and 600 mg)” NCT00352911 ↗ |
| Action | Inhibit | “a glucocorticoid receptor antagonist” NCT00043654 ↗ |
| Modality | Small molecule | “a 19 norsteroid with anti-progesterone and anti glucocorticoid activity” NCT03015701 ↗ |
| Route | Oral | “Mifepristone 5 MG capsule taken once daily by mouth” NCT00133705 ↗ |